Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Cipla
McKinsey
Baxter
Boehringer Ingelheim

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,958,326

« Back to Dashboard

Which drugs does patent 6,958,326 protect, and when does it expire?

Patent 6,958,326 protects BEYAZ, SAFYRAL, and YAZ, and is included in three NDAs.

This patent has seventy patent family members in thirty-eight countries.

Summary for Patent: 6,958,326
Title: Cyclodextrin-drospirenone inclusion complexes
Abstract:Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and .beta.-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
Inventor(s): Backensfeld; Thomas (Berlin, DE), Heil; Wolfgang (Berlin, DE), Lipp; Ralph (Berlin, DE)
Assignee: Schering AG (Berlin, DE)
Application Number:10/022,845
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,958,326
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,958,326
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation; Process;

Drugs Protected by US Patent 6,958,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 AB RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bayer Hlthcare SAFYRAL drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022574-001 Dec 16, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bayer Hlthcare YAZ drospirenone; ethinyl estradiol TABLET;ORAL 021676-001 Mar 16, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,958,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
00610135Dec 20, 2000

International Family Members for US Patent 6,958,326

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 032205 ➤ Sign Up
Austria 311204 ➤ Sign Up
Australia 1941802 ➤ Sign Up
Australia 2002219418 ➤ Sign Up
Australia 2006225232 ➤ Sign Up
Bulgaria 108002 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Covington
McKesson
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.